Twitter Beğeni Hilesi

Erasmus Hematology virtual lecture on Monday 21st at 16.00 CET. We have Dan Landau with "Charting clonal hematopoietic differentiation topologies with single-cell multi-omics". Link: us06web.zoom.us/j/85948655311 ID: 859 4865 5311 Spread the news!

Interested in single cell genomics but need help getting started? Check out the full agenda for our Single Cell Genomics Day next Friday (3/4). All talks will be live-streamed (no registration required) at satijalab.org/scgd22

Online Now: HiCAR is a robust and sensitive method to analyze open-chromatin-associated genome organization dlvr.it/SKRr0t

Finally, our HiCAR paper is online in Molecular Cell! Thanks to all the team members for their hard work, as well as the support from 4DNucleome and colleagues at Duke Regeneration Center DukeCAGT Duke GCB Duke Department of Cell Biology to make it possible!

A glimmer of hope for pediatric patients with #DIPG or other H3K27M-mutated DMGs Majzner_Lab Stanford Pediatrics Parker Institute for Cancer Immunotherapy Crystal Mackall Stanford Cancer Institute Michelle Monje🎗️. Read our summary and interview with the team here => ow.ly/nH8C50I2plt

Drug combinations can overcome therapy resistance but the number of possible combinations is vast. Today we published @nature a study using pharmacological screens in cancer cell lines and multi-omics analysis to identify effective combinations in defined molecular backgrounds.

Check out our new Seurat vignette on how to annotate and map scATAC-seq data using a scRNA-seq reference, and a 10x multiome dataset as a molecular 'bridge': Manuscript: biorxiv.org/content/10.110… Vignette: satijalab.org/seurat/article…

Our March issue is online! On the cover: Visualisation of the structure of the human cell cycle. cell.com/cell-systems/c…

Really chuffed to share our latest work from Sanjana Lab out in @nature today (nature.com/articles/s4158…). We tested >12,000 genes to find positive regulators of T cell proliferation to be used for next-gen #immunotherapies. A thread...

Excited to share the amazing work of Louai Labanieh who developed a best-in-class remote controlled CAR. SNIP-CAR is a bona fide safety switch with enhanced potency. Modulating drug dose can also enable safe targeting of shared antigens. #SNIP-CAR authors.elsevier.com/sd/article/S00…

Today our paper with Mackall Lab, Jay Spiegel Stanford BMT & Cell Therapy Stanford Department of Medicine is out in Nature Medicine! We found a CAR Treg subset in CD19-CAR T cells for lymphoma. We hope that this finding will put us on a path from 40% cure to 100% cure. rdcu.be/cVqVr

🚨New #SpatialTranscriptomics #Bioinformatics data resource out in Nature Methods. SODB, a platform with >2,400 manually curated spatial experiments from >25 spatial omics technologies & interactive analytical modules. This🧵will walk you through all the features of SODB [1/33]

Today our PhyloVelo paper came out in Nature Biotechnology. nature.com/articles/s4158…. PhyloVelo leverages both single-cell transcriptomic and lineage tracing information for RNA velocity field mapping. 1/3

Online now: Tumor-associated monocytes promote mesenchymal transformation through EGFR signaling in glioma dlvr.it/SvgSMq

Identifying predictors of glioma evolution from longitudinal sequencing | Science Translational Medicine science.org/doi/full/10.11…

B-cell lymphoma progression is accompanied by overexpression of an RNA exosome cofactor, ZCCHC7, alteration of 5.8S rRNA maturation, and translational rewiring nature.com/articles/s4158… Thank you for a great Collaboration Uttiya Basu #RNA #Ribosome

Our latest work out in Cancer Cell. #CART #immunometabolism #immunosuppression Inosine induces stemness features in CAR-T cells and enhances potency sciencedirect.com/science/articl…

Inosine makes CAR-T cells more stem-like and potent. It redirects their metabolism and reprograms their epigenome and transcriptome. An easy and feasible way to enhance CAR-T cell product potency at clinical scale! ✨💪🏻

New study in The Lancet: Ph 1 study in large B-cell #lymphoma (#LBCL) from Stanford Medicine suggests potential of CD22-directed CAR T-cell therapy (CAR22) for future #LBCL treatments: thelancet.com/journals/lance… (1/3)